443914-86-1

Basic information

• Product Name: 4-(4-Isopropylpiperazin-1-yl)aniline
• Synonyms: 4-(4-Isopropylpiperazin-1-yl)aniline;OTAVA-BB BB7020430015;4-[4-(propan-2-yl)piperazin-1-yl]aniline
• CAS NO: 443914-86-1
• Molecular Formula: C₁₃H₂₁N₃
• Molecular Weight: 219.33
• Mol File: 443914-86-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Isopropylpiperazin-1-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Isopropylpiperazin-1-yl)aniline(443914-86-1)
• EPA Substance Registry System: 4-(4-Isopropylpiperazin-1-yl)aniline(443914-86-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 443914-86-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(4-Isopropylpiperazin-1-yl)aniline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of specific medications. Its unique structure, including the piperazine ring and the isopropyl group, plays a significant role in enhancing the stability and solubility of the resulting compounds, which is essential for their efficacy and safety.
Used in Organic Compound Synthesis:
In the field of organic chemistry, 4-(4-Isopropylpiperazin-1-yl)aniline is utilized as a building block for the synthesis of a range of organic compounds. Its structural features make it a versatile component in the creation of new molecules with potential applications in various industries, including but not limited to pharmaceuticals, agrochemicals, and materials science.
Used in Medication Development:
4-(4-Isopropylpiperazin-1-yl)aniline is employed as a component in the development of certain medications, particularly those that require the specific properties conferred by the piperazine ring and the isopropyl group. Its role in these medications is to improve their pharmacological profiles, such as potency, selectivity, and bioavailability, which are critical for their therapeutic effectiveness.

Upstream product

• 260252-87-7 4-(4'-nitrophenyl)piperazine hydrochloride 
• 182618-86-6 tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 4318-42-7 1-(1-methylethyl)piperazine 
• 350-46-9 4-Fluoronitrobenzene 
• 443914-85-0 1-isopropyl-4-(4-nitrophenyl)piperazine 

Downstream Products

• 1031284-87-3 5-{8-[4-(4-isopropylpiperazin-1-yl)phenylamino]imidazo[1,2-a]pyridin-5-yl}-2,3-dihydro-isoindol-1-one 
• 1197165-06-2 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazin-1-yl)phenyl)urea 
• 1426260-17-4 N-(5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)-4-(pyridin-2-yl)benzamide 
• 1426259-96-2 N-(4-(4-isopropylpiperazin-1-yl)phenyl)-[1,1'-biphenyl]-4-carboxamide 
• 1197164-97-8 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazin-1-yl)phenyl)urea 
• 1031290-25-1 (5-chloroimidazo[1,2-a]pyridin-8-yl)-[4-(4-isopropylpiperazin-1-yl)phenyl]amine 
• 1025709-42-5 3-(1-cyclohexyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-N-(4-(4-isopropylpiperazin-1-yl)phenyl)azetidine-1-carboxamide 
• 872513-07-0 N-methyl-N'-[4-(4-isopropyl-piperazin-1-yl)-phenyl]-[1,3,5]triazine-2,4-diamine 
• 957345-90-3 (5-bromo-imidazo[1,2-a]pyrazin-8-yl)-[4-(4-isopropyl-piperazin-1-yl)-phenyl]-amine 

Relevant articles and documents

Pyrrolopyrimidine compound, pharmaceutical composition containing thereof, and preparation method and applications

The invention relates to a pyrrolopyrimidine compound represented by formula I, a pharmaceutical composition containing thereof, and a preparation method and applications in preventing or treating Weel protein kinase related diseases.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridine compounds are disclosed that have a formula represented by Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds of formula (I) that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

Novel triazolopyridine compounds are disclosed that have a formula represented by Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, ECM degradation, joint degradation and/or inflammation, and others.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following (formula I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS

The invention relates to heteroaryl aryl ureas of the formula (IA), wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.